Nonphysician-Implemented Multifaceted Intervention Beneficial in HTN

2024-06-20

THURSDAY, June 20, 2024 -- For older and younger adults with hypertension, a nonphysician-implemented, multifaceted, intensive blood pressure intervention can reduce the risk for cardiovascular disease (CVD) and all-cause mortality, according to a study published online June 18 in JAMA Cardiology.

Xiaofan Guo, M.D., Ph.D., from the First Hospital of China Medical University in Shenyang, and colleagues conducted a 48-month follow-up study of the China Rural Hypertension Control Project from 2018 to 2023. Participants recruited from 326 villages in rural China, aged 60 years and older and younger than 60 years, with a diagnosis of hypertension were included (22,386 and 11,609 individuals, respectively).

Among the older adults with hypertension, 11,289 and 11,097 were randomly assigned to a nonphysician, community health care practitioner-implemented multifaceted intervention to achieve blood pressure of less than 130/80 mm Hg and to a usual-care group, respectively. The researchers found a significantly lower rate of total CVD and all-cause mortality in the intervention group versus usual-care group (hazard ratios, 0.75 and 0.90, respectively). The risk reductions were also significant for total CVD, stroke, heart failure, and cardiovascular death among adults younger than 60 years (hazard ratios, 0.64, 0.64, 0.39, and 0.54, respectively). No significant between-group differences were seen in the incidences of injurious falls, symptomatic hypotension, syncope, and results for kidney outcomes in either age group.

"These results have substantial implications for the future of hypertension management among older adults who represent a large proportion of the population and high absolute risk for CVD complications," the authors write.

Abstract/Full Text

Editorial (subscription or payment may be required)

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

适应症